



Republic of the Philippines  
Department of Health  
**OFFICE OF THE SECRETARY**

1  
2 **ADMINISTRATIVE ORDER**

3 No. 2023- \_\_\_\_\_  
4  
5

6 **SUBJECT: Implementing Guidelines on the Schedule of Fees and Charges of**  
7 **the Food and Drug Administration for Licensing, Registration**  
8 **and Other Authorizations and Regulatory Services Repealing**  
9 **Administrative Order No. 50s. 2001, entitled, "Revised 2001**  
10 **Schedule of Fees and Charges for the Corresponding Services**  
11 **Rendered by the Bureau of Food and Drugs" and its Amendments**  
12  
13

14 **I. RATIONALE**  
15

16 The Food and Drug Administration (FDA) is mandated by Republic Act No. 9711 also  
17 known as the "Food and Drug Administration Act of 2009", to license all the establishments or  
18 facilities and issue product market authorization on all health products prior to manufacture,  
19 importation, exportation, sale, offering for sale, distribution, transfer, non-consumer use,  
20 promotion, advertising, or sponsorship. Accordingly, to protect public health and uphold  
21 consumer safety, the FDA conducts post-market surveillance of health products and  
22 establishments or facilities to ensure that adulterated, unregistered, or misbranded health  
23 products are not offered for sale or use.  
24

25 Pursuant to Article II A. Section 2.s. of the Implementing Rules and Regulations of the  
26 Republic Act (RA) No. 9711, the FDA is authorized to review its fees periodically and propose  
27 any increase and promulgate rules and regulations governing the collection of other related  
28 regulatory fees. Accordingly, under Article II B. Section 3 of the said Act, the FDA is  
29 authorized to collect, retain, and utilize or apply all fees, fines, royalties, and other charges  
30 collected by it under Section 31 of the Republic Act No. 9502 also known as the "Universally  
31 Accessible Cheaper and Quality Medicines Act of 2008" which includes upgrading of its  
32 facilities, equipment outlay, human resource development, and expansion; acquisition of the  
33 appropriate office space, as well as purchases of laboratory equipment and motor vehicles;  
34 upgrading of its current facilities and equipment and maintenance; funding for operating  
35 expenses of the central office laboratory divisions and satellite laboratories; and other activities  
36 or services of the FDA in the performance of its mandate  
37

38 With the current innovations in technology and the improvement of the country's  
39 economy evidenced by the flourishing volume of industries in health products, a commensurate  
40 increase in the fees and charges is considerably needed to be able to meet and sustain the  
41 increasing demands of providing the FDA stakeholders quality and efficient services. For more  
42 than twenty (20) years, the rate of fees and charges of the Food and Drug Administration has  
43 been referred to the Administrative Order No. 50 s.2001 or the Revised 2001 Schedule of Fees  
44 and Charges for the Corresponding Services Rendered by the Bureau of Food and Drugs. Thus,  
45 in view of the foregoing, a revisit and consequent repeal of Administrative Order No. 50 s. 2001  
46 is deemed in order.  
47

48 In the interest of the service and pursuant to the DOF-DBM-NEDA Joint Circular No.  
49 1-2013, also known as the “Implementing Rules and Regulations of Administrative Order No.  
50 31 s. 2012 on the Rationalization of Rates of Fees and Charges, Increase in Existing Rates and  
51 Imposition of New Fees and Charges”, the FDA is restructuring its fees and charges at a level  
52 commensurate with the cost of regulating health products, establishments or facilities to protect  
53 consumer safety and public health. Thus, the following guidelines are hereby adopted.  
54

## 55 **II. OBJECTIVE**

56  
57 This Administrative Order is issued to prescribe the schedule of fees and charges for  
58 the services rendered by the FDA and provide the guidelines for its implementation.  
59

## 60 **III. SCOPE**

61  
62 The new schedule of fees and charges shall apply to all persons, establishments or  
63 facilities and health products under FDA’s jurisdiction whether public or private, including but  
64 not limited to national and local government agencies, state colleges and universities, and  
65 schools, availing of FDA’s services.  
66

## 67 **IV. DEFINITION OF TERMS**

68  
69 For the purpose of implementing this Order, all terms used in this Order that are  
70 already defined in RA No. 3720 as amended by EO No. 175 and RA No. 9711 shall have the  
71 same meaning as defined therein. For emphasis, the following terms shall be defined as follows:  
72

- 73  
74
- 75 A. **Accreditation** refers to the attestation conveying a formal demonstration of a  
76 laboratory's competence and capability to carry out specific scientific and technical tests  
77 or analytical services with respect to health products.  
78
  - 79 B. **Authorization** refers to the permission embodied in a document granted by the FDA  
80 to a natural or juridical person who has submitted an application to implement the  
81 manufacture, importation, exportation, sale, offer for sale, distribution transfer, and or  
82 where appropriate, the use, testing, promotion, advertising, or sponsorship of health  
83 products. The authorization can take the form of a permit, a license, a certificate of  
84 registration, of accreditation, of compliance, or of exemption or any similar document.  
85
  - 86 C. **Center** refers to any of the following: Center for Cosmetics and Household/Urban  
87 Hazardous Substances Regulation and Research (CCHUHSRR), Center for Food  
88 Regulation and Research (CFRR), Center for Drug Regulation and Research (CDRR)  
89 and Center for Device Regulation, Radiation Health and Research (CDRRHR) of the  
90 FDA.  
91
  - 92 D. **Establishment** refers to the sole proprietorship, a partnership, a corporation an  
93 institution, an association or an organization engaged in the manufacture, importation,  
94 exportation, sale, offer for sale, distribution, donation transfer, use, testing, promotion,

95 advertising, or sponsorship of health products, including the facilities and installation  
96 needed for its activities.

97  
98 E. **Evaluation** refers to the process of reviewing submitted regulatory documents by  
99 applicants based on existing standards, rules, and regulations of the FDA.

100  
101 F. **Health Products** refers to food, drugs, cosmetics, devices, biologicals, vaccines, in-  
102 vitro diagnostic reagents, and household/urban hazardous substances and/or a  
103 combination of and/or a derivative thereof. It shall also refer to products that may have  
104 an effect on health which require regulations as determined by the FDA.

105  
106 G. **Health Product Vigilance** refers to the science and activities relating to the detection,  
107 assessment, understanding, and prevention of adverse effects or any other possible  
108 problems from Health Products.

109  
110 H. **Initial application** refers to the term used for a first-time or original application for any  
111 authorization as defined by RA No. 9711.

112  
113 I. **Micro Small Medium Enterprises (MSMEs)** refers to the definition according to  
114 Republic Act No. 9501 entitled “Magna Carta for Micro, Small and Medium Enterprises  
115 (MSMEs)” as any business activity or enterprise engaged in industry, agribusiness  
116 and/or services, whether single proprietorship, cooperative, partnership or corporation  
117 whose total assets, inclusive of those arising from loans but exclusive of the land on  
118 which the particular business entity’s office, plant and equipment are situated, must  
119 have value falling under the following categories: a.) Micro, not more than P3,000,000,  
120 b.) Small, P3,000,001 but not more than P15,000,000, and c.) Medium, P15,000,001 but  
121 not more than P100,000,000. More than P100,000,000 is considered a large enterprise.

122  
123 J. **Re-issuance** refers to the process of granting a duplicate copy of a valid authorization  
124 due to loss or damage of the original authorization. This is only applicable when the  
125 document issued by the FDA is a hard copy and not an electronic copy.

126  
127 K. **Renewal** refers to the process of filing an application for the extension of the validity  
128 of an authorization.

129  
130 L. **Risk-based Regulation** refers to the approach on regulating health products,  
131 establishments, and facilities by targeting activities that pose the highest risk to the  
132 public well-being, and in turn lowers the burden for a variety of lower-risk sectors and  
133 firms. Lowering burdens improves compliance and allows firms to benefit from a more  
134 level playing field. By directing the government resources towards the highest-risk  
135 areas, risk-based approaches also make the most of limited public resources and  
136 further improve accountability by enhancing transparency and predictability of  
137 requirements in given sectors and as applied to different establishments.

138  
139 M. **Variation and/or Amendment** refers to post-license changes in the status,  
140 circumstances, conditions, claims, or activities of authorized establishments, in  
141 accordance with existing guidelines.

144 **V. GUIDELINES**

145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191

- A. The new schedule of fees and charges is attached as Annexes A to F, as follows:
  - 1. Annex A for Fees on General Certification (Common to all Centers)
  - 2. Annex B for Center for Cosmetics and Household/Urban Hazardous Substances Regulation and Research (CCHUHSRR)
  - 3. Annex C for Center for Drug Regulation and Research (CDRR)
  - 4. Annex D for Center for Device Regulation Radiation Health and Research (CDRRHR)
  - 5. Annex E for Center for Food Regulation and Research (CFRR)
  - 6. Annex F for Common Services Laboratory (CSL)
  
- B. The application fees for granting an authorization/accreditation prescribed in this issuance shall cover but is not limited to the following activities :
  - 1. Receiving of application documents;
  - 2. Pre and Post Licensing Inspection of facilities for medical device;
  - 3. Pre-marketing activities, including but not limited to assessment, technical evaluation and pre-licensing inspection of establishment;
  - 4. Post-marketing surveillance of products and establishments, but not limited to the following:
    - a. Collection of samples;
    - b. Laboratory testing;
    - c. Complaints and reports processing;
    - d. Safety monitoring;
    - e. Post-licensing inspection;
    - f. Routine/special inspection;
    - g. Health Product Vigilance
    - h. Post evaluation;
    - i. Product verification;
    - j. Advertisement monitoring;
  - 5. Printing;
  - 6. Records management, archiving and administrative support;
  - 7. Government Courier services to deliver the authorization, if applicable;
  - 8. IT systems, maintenance, and development;
  - 9. Security Seal; and
  - 10. And all other related activities
  
- C. The application fees shall not cover the following expenses:
  - 1. UP Law Center’s Legal Research Fee (LRF) which is equivalent to P10.00 or 1% of the application fee, whichever is higher, as imposed by Republic Act (RA) No. 3870, as amended by Presidential Decree (PD) No. 200 and further amended by PD 1856, of which FDA is only the collecting agent as per Letter of Instruction No. 1182 dated 16 December 1981.
  - 2. Other fees incurred from the use of payment collection facilities, such as service fees charged by banks authorized by the FDA to collect its fees.
  - 3. Private/ Special Courier used for the conveyance of the certifications.

192 D. The FDA shall issue updated guidelines regarding new payment modes and methods  
193 as necessary.

- 194 1. Through Over-the-Counter at Landbank of the Philippines (LBP) using the  
195 LBP Oncoll Payment Slip;
- 196 2. Through Online LBP Link.BizPortal; or
- 197 3. Through Online Bills payment (Bancnet)
- 198 4. Other payment channels as may be determined by the FDA.

199

200 E. All payments shall be made not later than the date reflected in the Order of Payment  
201 (OP). Payments beyond the validity of the OP shall be automatically forfeited.

202

203 F. Application payments made including but not limited to the following, shall not be  
204 accepted and posted in the system:

205

- 206 1. Application payment with incomplete/insufficient amount paid;
- 207 2. Application payment with an incorrect reference number provided;
- 208 3. Application payment made through an unauthorized payment channel;
- 209 4. Application payment made beyond the validity of the issued FDA Order of  
210 Payment; and
- 211 5. Such other cases as determined by the FDA.

212

213 Applications with deficiency payment shall be posted after the proof of the full  
214 payment is made.

215

216 G. Changes and/or additions to the existing FDA payment channels shall be announced  
217 through a separate issuance.

218

219 H. The size of business operation used by CCHUHSRR and CFRR for licensing  
220 purposes (by asset) shall be in accordance with RA No. 9501 entitled "Magna Carta  
221 for Micro, Small and Medium Enterprises (MSMEs)" and its amendments.

222

223 I. Provision of support and assistance to MSMEs may be provided under the  
224 coordination of government efforts stipulated in RA No. 9501 Section 5c and its  
225 future amendments. Future related provisions will be carried out.

226

227 J. Flexibility in payment of fees and charges may be applied by the FDA in lieu of  
228 Public Emergency or State of Calamity declaration, provided, however, the  
229 following directives may be applied:

230

- 231 1. Upon recommendation of the FDA Director General for local public health  
232 emergency to be imposed by the DOH Secretary as declared by the Local  
233 Government Unit; or
- 234 2. Upon recommendation of the DOH Secretary and the FDA Director General  
235 to be imposed by the Office of the President following Republic Act 11517  
236 entitled "An Act Authorizing the President to Expedite the Processing and  
237 Issuance of National and Local Permits, Licenses and Certifications in  
238 Times of National Emergency"

239

240

241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289

**VI. VALIDITY**

The validity period for authorizations, permits, and certificates shall follow existing FDA issuances.

**VII. SURCHARGE OR PENALTY**

Consistent with R.A. No. 9711 and its IRR and other relevant FDA regulations, the conditions for the imposition of surcharge or penalty are provided below as follows:

A. Pursuant to Section 3, Paragraph (A) (2) and (B) (2) of Article 1, Book II on Licensing of Establishments and Registration of Health Products of IRR of RA 9711, applicable surcharge or penalty shall be imposed for applications for renewal of LTO or CPR received after the date of their expiration. This rule shall apply even in succeeding renewal applications.

B. An application for renewal of an LTO or CPR received after its date of expiration shall be subject to a surcharge or penalty equivalent to twice the renewal licensing fee and an additional 10% per month or a fraction thereof of continuing non-submission of such application within the maximum of one hundred twenty (120) days from its original expiry date.

C. The LTO or CPR shall be considered valid and existing until a decision or resolution by the FDA is rendered on the application for renewal.

D. LTO or CPR applications filed beyond the 120-day period shall be considered expired and the application shall be subject to a fee equivalent to the total surcharge or penalty plus the initial filing fee and the application shall undergo the corresponding filing and evaluation procedure.

**VIII. MANDATORY REVIEW**

The fees and charges shall be subject to mandatory review every three (3) years. The Policy and Planning Service shall undertake periodic review, conduct consultations with stakeholders, and recommend amendments to this Administrative Order to the Office of the Director-General for approval of the Secretary of Health, as may be deemed necessary.

**IX. REPEALING CLAUSE**

This Administrative Order effectively repeals the following issuances:

A. Administrative Order No. 50 s. 2001 entitled “Revised 2001 Schedule of Fees and Charges for the Corresponding Services Rendered by the Bureau of Food and Drugs”;

- 290 B. A.O. No. 18-A s. 1993 entitled “Standards of Quality and Requirements for the  
291 Processing, Packaging and Labelling of Bottled Drinking Water”;  
292
- 293 C. A.O. No. 15-A s. 1995 entitled “Guidelines Governing the Implementation of the  
294 Sangkap Pinoy Seal (SPS) Program and the Collection and Disbursement of Fees  
295 Generated from the Program”;  
296
- 297 D. A.O. No. 29, s.2000 entitled “Amendment to AO No. 23 s 1999 and AO No. 50,  
298 s.1999 Fees and Charges to be Collected by the Radiation Health Service”;  
299
- 300 E. DOH A.O. No. 47A s 2001 entitled “Rules and Regulations on the Registration,  
301 Including Approval and Conduct of Clinical Trials, and Lot or Batch Release  
302 Certification of Vaccines and Biologic Products”;  
303
- 304 F. A.O. NO. 82 s. 2003 entitled “Guidelines on the Granting of Diamond Sangkap  
305 Pinoy Seal to Manufacturers of Fortified Products”;  
306
- 307 G. A.O. No. 2008-0033 entitled “Rules and Conditions in Exempting Antibiotic Drug  
308 Products from Batch Certification Requirement Amending for this purpose Item III  
309 (C) and (D) of AO No. 103 s. 2002 “Batch Certification of Antibiotics” and for  
310 Other Purposes”;  
311
- 312 H. A.O. No. 2012-0024 entitled “Amendment to A.O. No. 50 s. 2001 Covering Fees  
313 and Charges for Accreditation of Bioequivalence Testing Centers and Private  
314 Testing Laboratories, as well as, Audits and Inspection”;  
315
- 316 I. FDA Circular No. 2011-004 entitled “Computation of Surcharge or Penalty  
317 Imposable in case of Submission of Renewal Applications Covering License of  
318 Establishments and Registration of Health Products *After* Their Date of Expiration  
319 Pursuant to Section 3, Paragraphs (A)(2) and (B)(2) of Article I of Book II of the  
320 RA 9711 Implementing Rules and Regulations, and Other Purposes”;  
321
- 322 J. FDA Circular No. 2013-001- entitled “ Revised Notification Template for Cosmetic  
323 Products” and its amendment;  
324
- 325 K. FDA Circular No. 2023-003 entitled “Guidelines on the Filing and Submission of  
326 Acceptable Variations on Protocols and Non-standard Protocols for the Review and  
327 Pre-Approval by the Food and Drug Administration Prior to the Conduct of Bio-  
328 efficacy Test Studies of Household Pesticides for the Purposes of Securing a  
329 Certificate of Product Registration”;  
330
- 331 L. FDA Circular No. 2015-001 entitled “Clarifications on the Regulations Governing  
332 Principal and Identical Drug Products as defined under Administrative Order No.  
333 2005-0031”.  
334  
335  
336  
337  
338

339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357

**X. SEPARABILITY CLAUSE**

If any provision is declared unauthorized or rendered invalid by any court of law or competent authority, those provisions not affected thereby shall remain valid and effective.

**XI. EFFECTIVITY DATE**

This Order shall take effect fifteen (15) days after its publication in the Official Gazette or in any newspaper of general circulation and upon filing with the University of the Philippines Law Center Office of the National Administrative Register.

**TEODORO J. HERBOSA, MD**  
Secretary of Health

358

Food and Drug Administration	Food and Drug Administration
<b>IRENE F. FLORENTINO-FARIÑAS, RPh, MD, MNSA</b> OIC Director III, Policy and Planning Service	<b>SAMUEL A. ZACATE, MD</b> Director General

359  
360

Keywords	
Related Issuances, laws, directives from other government agencies	Administrative Order No. 50 s. 2001 "Revised 2001 Schedule of Fees and Charges for the Corresponding Services Rendered by the Bureau of Food and Drugs"

361  
362